CXCL12 and Miyoshi myopathy: IBR has been shown to directly inhibit osteoclastic bone resorption and migration of SDF-1-induced MM cells, as well as to prevent the release of multiple osteoclast-derived tumor growth factors and the adhesion of MM cells to bone marrow stromal cells (BMSCs) [7,8,9].